Jason Elinoff MD
Critical Care Medicine, Pleural Disease, Pulmonary Vascular Medicine
CCMD
Join to View Full Profile
National Institutes of Health10 Center DR Bldg 10 RM 2C145Bethesda, MD 20892
Phone+1 301-496-9320
Dr. Elinoff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2008 - 2011
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2004 - 2007
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2004
Certifications & Licensure
MD State Medical License 2008 - 2026
MA State Medical License 2006 - 2009
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- Flow Cytometric Determination of Circulating Progenitor Cells in Patients With Pulmonary Arterial Hypertension: A Systematic Review.Kimia Heydari, Carrie Johnson, I Diane Cooper, Kadija Hersi, Carl Tanba
Pulmonary Circulation. 2025-01-01 - Evolution of Diffusing Capacity of the Lungs for Carbon Monoxide in Lymphangioleiomyomatosis: Historical Perspectives and the Role of Advanced Imaging.Bennett E Yang, Jason M Elinoff, Adrienne E Campbell-Washburn, Han Wen, Joel Moss
Chest. 2024-11-21 - Endothelial PHD2 deficiency induces apoptosis resistance and inflammation via AKT activation and AIP1 loss independent of HIF2α.Shuibang Wang, Keytam S Awad, Li-Yuan Chen, Mohammad A H Siddique, Gabriela A Ferreyra
American Journal of Physiology. Lung Cellular and Molecular Physiology. 2024-10-01
Press Mentions
Zymedi Announced Their Collaboration with the National Heart, Lung, and Blood Institute Through a CTA CRADA to Develop ZMA001 mAb, a Potential Treatment for Pulmonary Arterial Hypertension (PAH), a Rare, Female Predominant DiseaseJuly 3rd, 2023
Grant Support
- Proteasomal Degradation of XPB as a Novel Mechanism for Treating InflammationNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
- Proteasomal Degradation of XPB as a Novel Mechanism for Treating InflammationNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
- Cellular Models of PAH-Associated Molecular Defects as a Tool for Identifying New Therapeutic TargetsNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
- Cellular and Molecular Consequences of SARS-CoV2 Infection in Pulmonary Vascular EndotheliumNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
- Cellular Models of PAH-Associated Molecular Defects as a Tool for Identifying New Therapeutic TargetsNATIONAL HEART, LUNG, AND BLOOD INSTITUTEPresent
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
